State of Licensing 2011 Update

Size: px
Start display at page:

Download "State of Licensing 2011 Update"

Transcription

1 State of Licensing 2011 Update

2 Moderators/Speakers Hemmie Chang, Chair, Licensing & Strategic Alliance Practice Group, Foley Hoag LLP Ranya Dajani, Executive Director, Strategic Transactions Group, Bristol- Myers Squibb Mahmood Ladha, Executive Director Regional & Corporate Business Development, Global SPBD, AstraZeneca Veronique Riethuisen, Transactions Lead, Primary Care BD, Pfizer, Inc. R. Christopher Seaton, Senior V.P./Global Transactions, Bayer HealthCare 2

3 Overview Current Challenges for Partnering Developments & Innovations in Life Sciences Transactions Hot Areas Personalized Medicine/Diagnostics Emerging Markets Rare Diseases Pharma/University Partnerships 3

4 Overview Current Challenges for Partnering Developments & Innovations in Life Sciences Transactions Hot Areas Personalized Medicine/Diagnostics Emerging Markets Rare Diseases Pharma/University Partnerships 4

5 Life Sciences VC Funding Declining 5 Source: PricewaterhouseCoopers, Taking A Tumble, February 2011

6 Life Sciences VC Funding Declining Faster Than Overall VC Funding 6 Source: PricewaterhouseCoopers, Taking A Tumble, February 2011

7 Biotech IPOs Struggling in Q Company Name IPO Date Proceeds (M) Price Talk IPO Price 4/4/11 Price Pacira Pharmaceuticals 02/03/11 $42.00 $14-$16 $ BG Medicine 02/04/11 $35.00 $13-$15 $ Endocyte 02/04/11 $75.00 $13-$15 $ AcelRx Pharmaceuticals 02/11/11 $40.00 $12-$14 $ Tranzyme 04/01/11 $67.50 $11-$13 $ Source: Wall Street Journal Venture Capital Dispatch blog, Biotch IPOs Continue Bleeding Money, April 4, 2011

8 Biotech Post-IPO Performance: Percent Gain Or Loss Source: Google Finance IPOs through Feb. 18, 2011

9 Decline in M&A for Private Biotechs Number of Private Biotechs Acquired Source: Elsevier s Strategic Transactions database

10 10 BigPharma Facing Patent Cliff

11 Overview Current Challenges for Partnering Developments & Innovations in Life Sciences Transactions Hot Areas Personalized Medicine/Diagnostics Emerging Markets Rare Diseases Pharma/University Partnerships 11

12 Percentage of Deals Including An Option The Rise of Option-Based Licensing Source: Elsevier s Strategic Transactions. Includes all licensing deals by big pharma, big biotech in which the option is the main component from 1/01/2007 to 8/31/2010.

13 Up-Front Payments Declining Millions ($) 13 Source: Elsevier s Strategic Transactions. Data set includes 299 alliances by big pharma, mid-sized European companies, top Japanese, and big biotech for which up-fronts were disclosed Phase II average skewed by mammoth Abbott/Reata deal; if excluded average drops to $38.3mm.

14 Up-Front Payments Declining 14 Source: HBM Partners Pharma/Biotech M&A Report VC-backed companies only. Former buyouts excluded. Only for transactions where respective information was available.

15 What s Pharma Buying? Proportion of Total Worldwide Acquisition Value by Development Stage (includes generics) 15 Source: Elsevier s Strategic Transactions

16 The Rise of Contingent Value Rights Avg. Multiple Avg. Multiple with Earn-outs 16 Source: Elsevier s Strategic Transactions

17 Who is Buying? BigPharma s Share of Private Biotech Acquisitions Decreasing 17 Source: HBM Partners Pharma/Biotech M&A Report

18 Overview Current Challenges for Partnering Developments & Innovations in Life Sciences Transactions Hot Areas Personalized Medicine/Diagnostics Emerging Markets Rare Diseases Pharma/University Partnerships 18

19 Personalized Medicine/Diagnostics Deals in 2011 January launches $470M tender offer for February and and buys form partnership announce collaboration for $805M upfront March and form partnership April 19 raises $40M in Series A round from Third Rock Ventures

20 Overview Current Challenges for Partnering Developments & Innovations in Life Sciences Transactions Hot Areas Personalized Medicine/Diagnostics Emerging Markets Rare Diseases Pharma/University Partnerships 20

21 Pfizer buys 40% stake in Teuto Oct Amgen buys Bergamo April 2011 Emerging Markets Recent Deals Brazil Russia AstraZeneca invests in new production manufacturing plant, commits to support new science and technology center April India Bayer/Cadila Joint Venture January 2011 Partnership between Merck and Sun Industries, Ltd. April 2011 China Novartis acquires majority stake in Zhejian Tianyuan Bio-Pharmaceutical March 2011 Bristol-Myers Squibb and Simcere announce partnership Nov Merck/BGI sign Statement of Intent to Collaborate Sept. 2010

22 Overview Current Challenges for Partnering Developments & Innovations in Life Sciences Transactions Hot Areas Personalized Medicine/Diagnostics Emerging Markets Rare Diseases Pharma/University Partnerships 22

23 Alliances By Therapeutic Category Total Number of Alliances 23 Source: Elsevier s Strategic Transactions. Deal set includes all licensing transactions between 1/01/2007 and 12/31/2010 by big pharma, big biotechs, specialty, and top Japanese companies.

24 2010 s Top Dealmakers: Cancer, Neurology & Immune Disorders 24 Source: Elsevier s Strategic Transactions. Alliances that covered multiple theracats were counted more than once.

25 Rare Diseases Recent Deals Sanofi/Genzyme ($20B; numerous rare diseases) Pfizer/Zacharon Pharmaceuticals ($210M; lysosomal storage diseases) Pfizer/FoldRx Pharmaceuticals (protein misfolding diseases) 25

26 Rare Diseases FDA Designation & Approval Rates 26 Source: FDA Law Blog

27 Overview Current Challenges for Partnering Developments & Innovations in Life Sciences Transactions Hot Areas Personalized Medicine/Diagnostics Rare Diseases Emerging Markets Pharma/University Partnerships 27

28 Accessing Academic Innovation Total Number of Alliances 28 Source: Elsevier s Strategic Transactions. All licensing transactions by big pharma, big biotech, mid-sized European, and Top4 Japan from 1/01/2006 to 12/31/2010.

29 Pharma/University Partnerships Recent Deals Sanofi-aventis Enters Into Research Collaboration With Columbia University to Develop New Diabetes Treatments Yale and Gilead Sciences Sign Pact in Search for Cancer Drugs (up to $100 million) UCSF Partners With Pfizer to Improve Drug Discovery, Development (up to $85 million) AstraZeneca and UCL Join Forces in Sight-Related Stem Cell Medicine 29 Veridex (J&J), MGH (Harvard) to Work on Test for Circulating Tumor Cells

30 Q & A Hemmie Chang, Chair, Licensing & Strategic Alliance Practice Group, Foley Hoag LLP Ranya Dajani, Executive Director, Strategic Transactions Group, Bristol- Myers Squibb Mahmood Ladha, Executive Director Regional & Corporate Business Development, Global SPBD, AstraZeneca Veronique Riethuisen, Transactions Lead, Primary Care BD, Pfizer, Inc. R. Christopher Seaton, Senior V.P./Global Transactions, Bayer HealthCare 30

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,

More information

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D

Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer Eli Lilly and Company Washington Biotechnology &

More information

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION)

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION) THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION) Feedback from 93 Eastern-European patient groups PUBLISHED JULY 2016 CONTENTS ABOUT THIS REPORT Page 1 WHAT DID

More information

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update PwC Deals Q3 16 Update Executive summary Global Pharma and Life Sciences (PLS) deal activity declined both in volume and value this quarter compared to the prior quarter and Q3 15. The considerable decrease

More information

NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA

NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA Press release Baar, 28 January 2008 Attractive portfolio of investments in biotech and medical technology to be opened to the public HBM BioVentures announces further information of its planned IPO on

More information

Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector Publishing Intelligence Limited

More information

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through 2015 www.pharmsource.com 1 Presenters Jim Miller President and Founder, PharmSource Saul Richmond, PhD Director of Market Intelligence,

More information

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context

More information

Pharma - Biotech Collaborations: Optimizing Success, Minimizing Risk and Maintaining Alignment

Pharma - Biotech Collaborations: Optimizing Success, Minimizing Risk and Maintaining Alignment Presenter: Randall Sunberg Morgan Lewis May 16, 2008 In cooper Biography Randall Sunberg partner Morgan Lewis, Princeton Phone: 609.919.6606 Randall B. Sunberg is a partner in Morgan Lewis's Business and

More information

Monetizing Early-Stage R&D Assets. March 18, 2015

Monetizing Early-Stage R&D Assets. March 18, 2015 Monetizing Early-Stage R&D Assets March 18, 2015 Disclaimer Ernst & Young refers to the global organization of member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst

More information

How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners

How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners How attractive is the BioRegion of Catalonia for foreign investment? M ost

More information

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

Partnering and Product Development A Case Study of Inspiration Biopharmaceuticals, Inc.

Partnering and Product Development A Case Study of Inspiration Biopharmaceuticals, Inc. Partnering and Product Development A Case Study of Inspiration Biopharmaceuticals, Inc. LIFE SCIENCES LAW, PLLC Prepared for Carolina Innovations Seminar The Office of Technology Development at The University

More information

Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Roche's Global IP Strategy 10th. JIPA IP Symposium, Tokyo Dr. Axel Braun F. Hoffmann La Roche Ltd.

Roche's Global IP Strategy 10th. JIPA IP Symposium, Tokyo Dr. Axel Braun F. Hoffmann La Roche Ltd. Roche's Global IP Strategy 10th. JIPA IP Symposium, Tokyo 2011 Dr. Axel Braun F. Hoffmann La Roche Ltd. Content Roche Company Profile The IP Department Patent Filings Global Strategy Sales Overview IP

More information

CHINA MED DEVICE. China Medtech Will Continue Its Double Digit Growth in Years to Come

CHINA MED DEVICE.   China Medtech Will Continue Its Double Digit Growth in Years to Come China Medtech Will Continue Its Double Digit Growth in Years to Come The high level characteristics of medtech in China is focused here. Each of the 6 specific sectors according to SWS recommendation will

More information

Fall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE

Fall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Fall 2015 State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Industry Overview The expansion of Florida s biotech industry remains resilient with an overall growth rate of 92% in the number

More information

PROTECT Project. Joanna Groves Chief Executive Officer 27 April 2010 EFPIA Patient Think-Tank Brussels, Belgium

PROTECT Project. Joanna Groves Chief Executive Officer 27 April 2010 EFPIA Patient Think-Tank Brussels, Belgium PROTECT Project Joanna Groves Chief Executive Officer 27 April 2010 EFPIA Patient Think-Tank Brussels, Belgium Content of Presentation About IAPO Overview of PROTECT Work Package 4 - New methods for data

More information

Bayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division

Bayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Bayer Inc. Science for a Better Life Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Please review your career path to date, leading to your

More information

TRANSLATIONAL SCIENCE

TRANSLATIONAL SCIENCE TRANSLATIONAL SCIENCE A Discussion of Best Practices and Unique Models Wednesday January 31, 2018 at The NYSCF Research Institute HRA TRI-STATE REGIONAL MEETING 31 Wednesday January, 2018 AGENDA 8:30 AM

More information

PHARMA S NEW PHASE. Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom. They re back.

PHARMA S NEW PHASE. Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom. They re back. Renew-New PHARMA S NEW PHASE Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom They re back. Mergers & acquisitions, that is and in a big way. Wall Street and City

More information

Trends in Terms of U.S. Life Science Venture Financings. Full Year Fenwick. fenwick & west llp

Trends in Terms of U.S. Life Science Venture Financings. Full Year Fenwick. fenwick & west llp 2012 Trends in Terms of U.S. Life Science Venture Financings Full Year 2012 Fenwick fenwick & west llp 2012 Trends in Terms of U.S. Life Science Venture Financings Full Year 2012 Survey Intro and Background

More information

GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS

GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS PHM006K March 2016 Himani Singhi Wadhwa Project Analyst ISBN: 1-62296-254-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481

More information

HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio

HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio SECA conference Zurich, 3 July 2013 Dr. Andreas Wicki, CEO HBM at a Glance SIX-listed investment company

More information

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Financing Growth Ventures to Minimize Equity Dilution

Financing Growth Ventures to Minimize Equity Dilution Financing Growth Ventures to Minimize Equity Dilution An entrepreneurial team s mission is to develop and grow its venture and to optimize the management team s equity ownership stake. Significant growth

More information

Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile

Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business

More information

August 17, The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio

August 17, The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio Joint Democratic and Republican House Policy Committee Hearing August 17, 2016 The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio Chairman Benninghoff, Chairman Sturla, and members

More information

Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market

More information

Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Venture Capital Search Highlights

Venture Capital Search Highlights Venture Capital Venture funding continued at the strongest pace witnessed over the past decade in 2016, and recruiting the future leaders of the industry s emerging growth companies has never been more

More information

VentureSource Europe -- 3Q 2014

VentureSource Europe -- 3Q 2014 Europe -- 3Q 2014 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, and liquidity. The included charts and graphs offer a

More information

gellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) Web gellerbp.

gellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) Web gellerbp. gellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) 315-0600 Web gellerbp.com Summary Personal Diverse, world-class team of top biotech bankers,

More information

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within

More information

Venture Capital Report

Venture Capital Report Venture Capital Report Europe 1Q 2018 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, valuation, and liquidity. The included

More information

Associate Director. Biomarker Operations Lead. Business Development & Strategic Alliances. Business Development Executive

Associate Director. Biomarker Operations Lead. Business Development & Strategic Alliances. Business Development Executive Job Title Alliance Lead Analytics Specialist Associate Director Associate Director Diagnostics Partnering Associate Director Business Development Associate Director Application Architecture Associate Manager

More information

IVC-MEITAR HIGH-TECH EXITS H1/ 2015 REPORT. IVC-Meitar 2014 Exits Report Prepared by IVC Research Center Ltd.

IVC-MEITAR HIGH-TECH EXITS H1/ 2015 REPORT. IVC-Meitar 2014 Exits Report Prepared by IVC Research Center Ltd. IVC-MEITAR HIGH-TECH EXITS H1/ 215 REPORT IVC-Meitar 214 Exits Report Prepared by IVC Research Center Ltd. Israeli High-Tech Exit Highlights Exit proceeds in H1/215 reached ¾ of total exits for 214 Average

More information

Publication Date Reporter Pharma Boardroom 24/05/2018 Staff Reporter

Publication Date Reporter Pharma Boardroom 24/05/2018 Staff Reporter Publication Date Reporter Pharma Boardroom 24/05/2018 Staff Reporter Pharma Boardroom An Exclusive Interview with Jonathan Hunt CEO, Syngene International, India. Jonathan Hunt, CEO of Syngene International,

More information

Agenda. Genesys Capital Partners. The Opportunity. Our Approach

Agenda. Genesys Capital Partners. The Opportunity. Our Approach MEDT Dinner Presentation September 28, 2005 Agenda Genesys Capital Partners The Opportunity Our Approach Genesys Capital Partners Genesys Capital Partners Successful Track Record Management experience

More information

LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter)

LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Aqua Pharmaceuticals, LLC

Aqua Pharmaceuticals, LLC Aqua Pharmaceuticals, LLC Corporate Presentation June 2011 AQUA PHARMACEUTICALS, LLC 1 Company Overview Specialty dermatology pharmaceutical company currently focusing on acquiring, developing and marketing

More information

Venture Capital Report

Venture Capital Report Venture Capital Report Europe 3Q 2015 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, valuation, and liquidity. The included

More information

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector

More information

NVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations

NVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations February 11-12, 2019 New York Marriott Marquis Now in its 21 st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and

More information

Omeros Raises More Than $63 Million in Financing

Omeros Raises More Than $63 Million in Financing Omeros Raises More Than $63 Million in Financing Seattle, WA February 12, 2007 Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors,

More information

BREAKTHROUGH CONVENTION SUMMARY JUNE SAN DIEGO CONVENTION.BIO.ORG #BIO2017

BREAKTHROUGH CONVENTION SUMMARY JUNE SAN DIEGO CONVENTION.BIO.ORG #BIO2017 BREAKTHROUGH CONVENTION SUMMARY JUNE 19-22 SAN DIEGO CONVENTION.BIO.ORG #BIO BIO BY THE NUMBERS FEATURING SEVERAL THEMATIC EXHIBITS 16,123 ATTENDEES 74 48 COUNTRIES STATES 18,000 MORE THAN EXHIBITORS 41,400

More information

MassMEDIC Annual Meeting

MassMEDIC Annual Meeting MassMEDIC Annual Meeting Sector and Massachusetts EvaluateMedTech Analysis Tom Sommer, President MassMedic Celebrating 20 years Founded in 1996 350+ member companies Played a key role in the FDA Modernization

More information

INSTITUTE OF MEDICINE COMMITTEE ON THE U.S. COMMITMENT TO GLOBAL HEALTH

INSTITUTE OF MEDICINE COMMITTEE ON THE U.S. COMMITMENT TO GLOBAL HEALTH INSTITUTE OF MEDICINE COMMITTEE ON THE U.S. COMMITMENT TO GLOBAL HEALTH Sharing Information, Knowledge and Materials Dr. Ashley J. Stevens Executive Director, Technology Transfer Senior Research Associate

More information

Venture Capital Report

Venture Capital Report Europe 4Q 2014 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, valuation, and liquidity. The included charts and graphs

More information

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis

More information

1h Fenwick. Trends in Terms of U.S. Life Science Venture Financings. First Half fenwick & west llp

1h Fenwick. Trends in Terms of U.S. Life Science Venture Financings. First Half fenwick & west llp 1h 2012 Trends in Terms of U.S. Life Science Venture Financings First Half 2012 Fenwick fenwick & west llp 1h 2012 Trends in Terms of U.S. Life Science Venture Financings First Half 2012 Survey Introduction

More information

Medtech Slowdown. Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year

Medtech Slowdown. Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year www.pwc.com Medtech Slowdown Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year February 2014 2 PwC US venture capital funding for

More information

Using Academic Licensing Agreements to Promote Global Social Responsibility

Using Academic Licensing Agreements to Promote Global Social Responsibility Using Academic Licensing Agreements to Promote Global Social Responsibility Equitable Licensing of Medical Research Results Charité - Universitätsmedizin Berlin April 26, 2009 Dr. Ashley J. Stevens Executive

More information

CANADIAN PRIVATE EQUITY BUYOUT REVIEW

CANADIAN PRIVATE EQUITY BUYOUT REVIEW CANADIAN PRIVATE EQUITY BUYOUT REVIEW First Half 2016 REUTERS Table of Contents Canada s PE Buyout Market in Q2 2016 3 $ Invested and # Companies Financed 5 Top Buyout Deals 9 Canada by Market Segment

More information

Management to Host Conference Call at 8:30 a.m. ET today

Management to Host Conference Call at 8:30 a.m. ET today Aclaris Therapeutics Reports Second Quarter 2016 Financial Results August 11, 2016 7:01 AM ET Management to Host Conference Call at 8:30 a.m. ET today MALVERN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:ACRS),

More information

Form FI. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007.

Form FI. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007. Form 51-102FI SERNOVA CORP. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007. The following discussion and analysis should be

More information

Purvi B. Maniar Member of the Firm

Purvi B. Maniar Member of the Firm Purvi B. Maniar Member of the Firm New York 250 Park Avenue New York, New York 10177 Tel: 212-351-3757 Fax: 212-878-8600 St. Louis Tel: 314-395-2775 pmaniar@ebglaw.com PURVI B. MANIAR is a Member of the

More information

For personal use only

For personal use only 2011 Annual General Meeting December 1, 2011 NASDAQ (UNIS) and ASX (UNS) Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor

More information

The 2011 EU industrial R&D investment SCOREBOARD

The 2011 EU industrial R&D investment SCOREBOARD 1 The 2011 EU industrial R&D investment SCOREBOARD Joint Research Centre European Commission Héctor Hernández Alex Tuebke Fernando Hervás 1. Background 2 Understanding the dynamics of industrial R&D at

More information

Generics Series: Authorized Generics Analysis Stemming the Generics Tide

Generics Series: Authorized Generics Analysis Stemming the Generics Tide Generics Series: Authorized Generics Analysis Stemming the Generics Tide Report summary An overview of the authorized generics landscape, including drivers and resistors for both branded and generics players

More information

Innovation and the Changing Practice of Medicine

Innovation and the Changing Practice of Medicine Innovation and the Changing Practice of Medicine Japan Medical Innovation Symposium David Epstein, Division Head Novartis Pharmaceuticals Tokyo, August 18, 2015 Agenda The Case for Innovation How Novartis

More information

DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market research

More information

Dealdoc. Acquisition agreement for Gambro. Baxter International Gambro. Dec , Wildwood Ventures Ltd. All rights reserved.

Dealdoc. Acquisition agreement for Gambro. Baxter International Gambro. Dec , Wildwood Ventures Ltd. All rights reserved. Dealdoc Acquisition agreement for Gambro Baxter International Gambro Dec 04 2012 Acquisition agreement for Gambro Companies: Baxter International Gambro Announcement date: Dec 04 2012 Deal value, US$m:

More information

Guidelines for Facilitating the Use of Research Tool Patents in the Life Sciences. March 1, 2007 Council for Science and Technology Policy

Guidelines for Facilitating the Use of Research Tool Patents in the Life Sciences. March 1, 2007 Council for Science and Technology Policy Guidelines for Facilitating the Use of Research Tool Patents in the Life Sciences March 1, 2007 Council for Science and Technology Policy 1. Introduction (1) In the domains of medicine and biotechnology,

More information

THE BUSINESS OF THE BRAIN 2.0 ACCELERATING PROGRESS TOWARD CURES

THE BUSINESS OF THE BRAIN 2.0 ACCELERATING PROGRESS TOWARD CURES THE BUSINESS OF THE BRAIN 2.0 ACCELERATING PROGRESS TOWARD CURES Join us for a very special program co-hosted the HBS Alumni of Boston (HBSAB), The Harvard Stem Cell Institute (HSCI), and the Harvard NeuroDiscovery

More information

Crack the Code: Demystify the Success Factors for Career Development

Crack the Code: Demystify the Success Factors for Career Development Crack the Code: Demystify the Success Factors for Career Development March 1, 2014, Saturday Rutgers University 675 Hoes Lane West Piscataway, NJ 08854 Sino-American Pharmaceutical Professionals Association

More information

Private Equity and Venture Capital in Switzerland

Private Equity and Venture Capital in Switzerland Private Equity and Venture Capital in Switzerland Venture Valuation VV AG Badenerstr. 18 8004 Zurich Switzerland Phone +41 (43) 321 86 60 Fax + 41 (43) 321 86 61 info@venturevaluation.ch Agenda - Overview

More information

VENTURE-BACKED IPO EXIT ACTIVITY MORE THAN DOUBLES IN Q WITH STRONGEST QUARTER FOR BIOTECH OFFERINGS SINCE 2000

VENTURE-BACKED IPO EXIT ACTIVITY MORE THAN DOUBLES IN Q WITH STRONGEST QUARTER FOR BIOTECH OFFERINGS SINCE 2000 CONTACTS Laura Cruz Tenor Communications for NVCA 1.917.406.7517 laura@tenorcom.com Lauren Herman Thomson Reuters 1.646.223.5985 lauren.herman@thomsonreuters.com VENTURE-BACKED IPO EXIT ACTIVITY MORE THAN

More information

Feature. Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia. 2020, our goal is to become #1 in

Feature. Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia. 2020, our goal is to become #1 in Feature Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia Based on our long-term strategic vision toward 2020, our goal is to become #1 in Asia in terms of our

More information

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis. DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Year(s): 2015 Name: Patrick Pun, MD Title: Asasistant Professor of Medicine Address: DCRI Please complete the applicable rows in the following table. Monetary

More information

Supporting Innovation through Regulation and Science

Supporting Innovation through Regulation and Science Supporting Innovation through Regulation and Science Larry O Dwyer, Scientific Affairs Manager PEARRL Regulatory Science Symposium 21 st June 2017, School of Pharmacy, UCC Overview of Presentation Drivers

More information

TRANSFORMING THE FUTURE

TRANSFORMING THE FUTURE FIRST. TRANSFORMATIVE. PROVEN. TRANSFORMING THE FUTURE NASDAQ : TINY SAFE HARBOR STATEMENT This presentation may contain statements of a forward-looking nature relating to future events. Statements contained

More information

Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast,

Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast, Transparency Market Research Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 2018 Buy Now Request Sample Published Date: Mar 2013 Single User

More information

WILSON SONSINI GOODRICH & ROSATI

WILSON SONSINI GOODRICH & ROSATI WILSON SONSINI GOODRICH & ROSATI IS PLEASED TO ANNOUNCE THAT THE FOLLOWING ATTORNEYS HAVE BECOME PARTNERS AT THE FIRM. Troy Foster Corporate & Securities, Palo Alto Jessica L. Margolis Litigation, New

More information

Daryn A. Grossman. Proskauer.com. Partner. New York

Daryn A. Grossman. Proskauer.com. Partner. New York Contact Daryn A. Grossman Partner New York +1.212.969.3665 dgrossman@proskauer.com Daryn A. Grossman is co-chair of Proskauer s global Corporate Department. She serves as the head of the Life Sciences

More information

Presentation to Medicon Valley Alliance Crescendo Conference. Frank Yu Founder, CEO & CIO Ally Bridge Group Themes Investment Partners

Presentation to Medicon Valley Alliance Crescendo Conference. Frank Yu Founder, CEO & CIO Ally Bridge Group Themes Investment Partners CHINA GLOBAL CHINA Presentation to Medicon Valley Alliance Crescendo Conference Frank Yu Founder, CEO & CIO Ally Bridge Group Themes Investment Partners October 2013 0 We are an Ally and a Bridge. We are

More information

Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2010)

Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2010) Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2010) Background We analyzed the terms of venture financings for 126 companies headquartered in Silicon Valley that reported raising

More information

Biotech Concerto #6 Investment Process December 2008

Biotech Concerto #6 Investment Process December 2008 Biotech Concerto #6 Investment Process December 2008 Index Biotech Investment Characteristics Investment Policy Investment Team Scientific Advisory Board Deal Flow Attrition Rate From Screening to Decision

More information

Financing Sources, Sales Pitch to Investors BARCELONA Aitana Peire Venture Valuation

Financing Sources, Sales Pitch to Investors BARCELONA Aitana Peire Venture Valuation 30.04.2014 Aitana Peire Venture Valuation Venture Valuation Mission Independent assessment and valuation of technology driven companies / products in growth industries Information services / Life Sciences

More information

FOREST LABORATORIES, INC. AND DAIICHI SANKYO, INC. ANNOUNCE THE TERMINATION OF THE AZOR CO-PROMOTION AGREEMENT

FOREST LABORATORIES, INC. AND DAIICHI SANKYO, INC. ANNOUNCE THE TERMINATION OF THE AZOR CO-PROMOTION AGREEMENT For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

More information

The MoneyTree Report. Overview of Venture Capital Investments Third Quarter 2009

The MoneyTree Report. Overview of Venture Capital Investments Third Quarter 2009 The MoneyTree Report Overview of Venture Capital Investments Third Quarter 2009 PricewaterhouseCoopers/National Venture Capital Association MoneyTree Report based on data from Thomson Reuters 1 Host of

More information

PRISME Technical Forum Introduction Accelerating Disruption

PRISME Technical Forum Introduction Accelerating Disruption PRISME Technical Forum Introduction Accelerating Disruption Presenters: Matthew Rich and Jim Golden Agenda Following the Money: Venture Capital s Influence on Pharma Tech Applications and Possibilities

More information

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Duke COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report current and anticipated information for the

More information

ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Annual Press Conference Financial year 2017

Annual Press Conference Financial year 2017 Annual Press Conference 2018 Financial year 2017 Financial year Hubertus von Baumbach Chairman of the Board of Managing Directors 2017 Highly successful financial year 2017 Major success with human pharmaceuticals

More information

Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting

Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting Tokyo, Japan March 16, 2010 Astellas Pharma Inc. (TSE: 4503) today notified

More information

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis. DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Year(s): 2016 Name: Shelby D. Reed, PhD Title: Professor Address: PO Box 17969, Durham, NC 27715 Please complete the applicable rows in the following table.

More information

Digital Health Funding and M&A

Digital Health Funding and M&A Digital Health Funding and M&A 2018 Third Quarter and Nine Month Report Funding and Merger & Acquisition activity for the Digital Health sector http://www.mercomcapital.com 1 Copyright 2010-2016 Mercom

More information

Financing Alternatives for Biotechnology Companies: A Case Study of Seattle Genetics

Financing Alternatives for Biotechnology Companies: A Case Study of Seattle Genetics 1 Financing Alternatives for Biotechnology Companies: A Case Study of Seattle Genetics Eric Dobmeier Chief Business Officer Life science startups are the only companies that are forced to define their

More information

Observations from Pharma

Observations from Pharma Observations from Pharma Indian Patent Enforcement in the Chemical Arts Gurmeet Kaur Sidhu, Senior Patent Litigation Counsel London, 26/9/11 a Novartis company The Indian Pharmaceutical sector: Overview

More information

Licensing League Tables 3Q14

Licensing League Tables 3Q14 BioPharm Insight Licensing League Tables Table of Contents League Tables Global League Tables of Legal Advisors for...2 Global League Tables of Legal Advisors for...3 North American League Tables of Legal

More information

The percentage of Series A rounds declined significantly, to 12% of all deals.

The percentage of Series A rounds declined significantly, to 12% of all deals. Silicon Valley Venture Capital Survey Fourth Quarter 2012 Barry Kramer and Michael Patrick Fenwick fenwick & west llp Background We analyzed the terms of venture financings for 116 companies headquartered

More information

Scripps Florida. Accelerating Discoveries, Saving Lives. Presentation to the Urban Land Institute November 4, 2011

Scripps Florida. Accelerating Discoveries, Saving Lives. Presentation to the Urban Land Institute November 4, 2011 Scripps Florida Accelerating Discoveries, Saving Lives Presentation to the Urban Land Institute November 4, 2011 Alex Bruner Associate Vice President, Philanthropy 1921- Founding of the Scripps Metabolic

More information

Life Sciences Outlook

Life Sciences Outlook New Jersey 2018 JLL Research Report Life Sciences Outlook Breakthrough discoveries at a breathtaking pace 2 New Jersey The pharmaceutical/life sciences industry has historically been one of New Jersey

More information

Doing (IP) Business in BRIC Countries

Doing (IP) Business in BRIC Countries Doing (IP) Business in BRIC Countries WIPO Conference, November 2016 Dr. Joerg Thomaier, Head of IP Bayer Group Agenda A Public Contract called Patent Law Brazil Russia India China BRIC Comparison Summary

More information